Jon Saxe

Cell Pathways, Inc. develops and commercializes drugs for the prevention and treatment of cancer

Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA.

Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA.

Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA.

BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO.

POINT Biomedical Corp. develops biomedical-imaging products. It manufactures products for diagnostic, molecular imaging, and drug delivery applications based on biSphere technology. The company was founded in 1996 and is headquartered in San Carlos, CA.

Arbor Vita Corp. engages in discovery and developing of drugs. It targets cellular regulators, PDZ proteins, to accelerate the discovery and development of human therapeutics, and diagnostics. The company was founded by Peter S. Lu in 1998 and is headquartered in Fremont, CA.

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Excaliber Enterprises Ltd. is a development stage company. It is engaged in the business of selling specialty gift baskets to health care professionals, organizations and patients, and real estate agents and firms. The company was founded on October 6, 2005 and is headquartered in Rathdrum, ID.

Cancer Prevention Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of therapeutic agents for the treatment and prevention of certain pre-cancerous conditions, orphan diseases and gastrointestinal conditions. The company’s pipeline consists of Gastrointestinal and Orphan. Cancer Prevention Pharmaceuticals was founded by Dr. Frank Meyskens and Gene Gerner in June 9, 2008 and is headquartered in Tucson, AZ.

Achelios Therapeutics, Inc. operates as a bio-pharmaceutical development company. It specializes in non-steroidal anti-inflammatory drug. The company was founded by Crist J. Frangakis and is headquartered in Chaple Hill, NC.

Institutional Venture Partners (Institutional Venture Partners) is a venture capital firm founded in 1980 by Reid Dennis. The firm is headquartered in Menlo Park, California.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom.

PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV.

Amalyte Pharmaceuticals, Inc. develops therapies for the treatment of immune and inflammatory diseases. The company is based in San Francisco, CA. Amalyte Pharmaceuticals was acquired by Kemin Industries, Inc. on June 04, 2009.

A-CUBE, Inc. develops novel antibodies. It utilizes silico algorithms and to discover novel druggable targets suitable for developing human therapeutic interventions, including next generation drugs for commercially proven targets. The company was founded by Nobuyuki Ota is headquartered in Belmont, CA.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.

Arcuo Medical, Inc. manufactures surgical and medical instruments.

Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA.

Nuvox Pharma LLC operates as biotechnology company. Its publication includes acute hypoxemic respiratory failure, hermorrrhagic shock, mechanism of action, myorcardial infarction, oncology, pharmacokinetics, stroke, and traumatic brain injury. The company was founded by Evan Unger and is headquartered in Tucson, AZ.

Epalex Corp. engages in the development of novel treatments for migraine and epilepsy. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. The firm also develops transformational products for seizure prophylaxis in patients suffering from primary generalized epilepsies. The company was founded Randall B. Murphy and is headquartered in Palo Alto, CA.

NuvOx Therapeutics, Inc. is a clinical stage biotechnology company that develops oxygen therapeutics. The company is based in Tucson, AZ. NuvOx Therapeutics was founded by Jennifer Johnson, Evan C. Unger. Evan C. Unger has been the CEO since incorporation.